Furthermore, CX-5461 demonstrated more potent activity in an aggressive MLL-ENL*Nras model of AML that was resistant to standard therapy, a regime of Cytarabine—Doxorubicin administered at MTD [8]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.